GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Russian bomb factory acquiring Siemens technology amid sanctions - Global Banking & Finance Review
Image illustrating the Biysk Oleum Factory's acquisition of Siemens equipment via intermediaries, highlighting the circumvention of Western sanctions. This reflects ongoing military production efforts in Russia.
Finance

Poland watchdog fines Neuca in decade-long drug pricing cartel

Published by Global Banking & Finance Review

Posted on September 21, 2026

2 min read

· Last updated: September 21, 2026

Add as preferred source on Google

Neuca Fined $131 Million in Poland's Decade-Long Drug Pricing Cartel

Poland's UOKiK Imposes Record Fines on Pharmaceutical Wholesalers

Background of the Cartel and Regulatory Action

Sept 21 (Reuters) - Poland's competition regulator UOKiK said on Monday it fined pharmaceutical wholesaler Neuca 499 million zlotys ($131 million) for participating in a pricing cartel that lasted more than a decade, sending its shares sharply lower.

Scope of the Fines and Market Impact

The penalty was the largest in a total 905 million zloty fine against four wholesalers that shared drug pricing data for more than 10 years, UOKiK said. The regulator added that the three largest groups controlled more than 70% of Poland's wholesale drug market.

Neuca's Response and Legal Proceedings

• Neuca said it disagrees entirely with the charges and plans to appeal to Poland's Court of Competition and Consumer Protection.

Details of the Cartel's Operations

• UOKiK said wholesalers accessed pharmacy purchasing data through loyalty programmes, allowing them to see rivals' prices and terms for individual pharmacies and adjust their own offers.

Market Reaction and Further Developments

• As of 1045 GMT, shares of the company were down 15.6%, on track for the highest single-day fall ever.

Leniency Program and Cooperation

• Polska Grupa Farmaceutyczna avoided any financial penalty by cooperating with investigators under UOKiK's leniency program and providing evidence.

Appeals Process

• The decision is not final and companies may appeal to court.

Additional Information

($1 = 3.7921 zlotys)

(Reporting by Rafal Nowak; editing by Bartosz Dabrowski)

Key Takeaways

  • Neuca received the largest individual fine (PLN 499 million) in a total PLN 905 million penalty against four wholesalers for over‑10‑year collusion via loyalty‑program data sharing (uokik.gov.pl)
  • The three biggest wholesalers controlled over 70% of Poland’s drug wholesale market, enabling anti‑competitive pricing coordination (uokik.gov.pl)
  • Polska Grupa Farmaceutyczna avoided fines by cooperating under UOKiK’s leniency program; Neuca disputes the charges and plans to appeal (uokik.gov.pl)

References

Frequently Asked Questions

Why was Neuca fined by Poland's competition regulator?
Neuca was fined for participating in a drug pricing cartel that lasted over a decade, sharing drug pricing data with rivals.
How much was Neuca fined in the cartel case?
Neuca received a fine of 499 million zlotys ($131 million) from Poland's UOKiK.
Did Neuca admit to the cartel charges?
Neuca disagreed entirely with the charges and plans to appeal to Poland's Court of Competition and Consumer Protection.
Which company avoided financial penalties in the case?
Polska Grupa Farmaceutyczna avoided penalties by cooperating with investigators under UOKiK's leniency program.
What impact did the news have on Neuca's share price?
Neuca's shares dropped by 15.6%, marking the highest single-day fall ever for the company.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category